{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:01:12Z","timestamp":1792008072203,"version":"4.4.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Alexion, AstraZeneca Rare Disease"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"published-print":{"date-parts":[[2025,4]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n This phase 2, double-blind, randomized controlled trial evaluated the complement C5 inhibitor, ravulizumab, in adults with IgA nephropathy.<\/jats:p>\n <\/jats:list-item>\n \n A 30.1% (90% confidence interval, 13.7% to 43.5%) relative reduction in proteinuria for ravulizumab versus placebo was observed at approximately 6 months.<\/jats:p>\n <\/jats:list-item>\n \n Treatment with ravulizumab was well tolerated.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n The complement system plays a central role in the pathogenesis of IgA nephropathy. We present findings from a phase 2 trial of ravulizumab, a complement C5 inhibitor.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n The Study of Ravulizumab in Proliferative Lupus Nephritis or IgA Nephropathy (NCT04564339) was a randomized, double-blind, placebo-controlled trial of ravulizumab in addition to standard of care. Adults with IgA nephropathy, proteinuria \u22651 g\/d, and eGFR \u226530 ml\/min per 1.73 m\n 2<\/jats:sup>\n , and on stable renin-angiotensin blockade were randomized 2:1 to ravulizumab (intravenous every 8 weeks) or placebo for 26 weeks. From week 26\u201350, all participants received open-label ravulizumab. The primary end point was percentage change in proteinuria from baseline to week 26. Secondary end points included change in proteinuria at week 50 and eGFR. Safety, pharmacokinetics, and pharmacodynamics were evaluated.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Forty-three patients were randomized to ravulizumab and 23 to placebo. At week 26, a statistically significant reduction in proteinuria was observed with ravulizumab versus placebo: \u221241.9% (95% confidence interval [CI], \u221250.2% to \u221232.0%) change in urine protein with ravulizumab and \u221216.8% (95% CI, \u221231.8% to 1.6%) change with placebo (30.1% treatment effect;\n P<\/jats:italic>\n = 0.005). At week 50, there was a \u221244.8% (95% CI, \u221255.1% to \u221232.1%) change from baseline in urine protein with ravulizumab, and in patients who crossed over from placebo to ravulizumab at week 26, the change from baseline (week 0) to week 50 was \u221245.1% (\u221258.0% to \u221228.4%). The least squares mean change in eGFR from baseline to week 26 with ravulizumab was 0.2 (95% CI, \u22122.3 to 2.7) ml\/min per 1.73 m\n 2<\/jats:sup>\n and with placebo was \u22124.5 (\u22127.9 to \u22121.1) ml\/min per 1.73 m\n 2<\/jats:sup>\n . From baseline to week 50, the least squares mean change in eGFR with ravulizumab was \u22123.9 (95% CI, \u22126.4 to\u22121.3) ml\/min per 1.73 m\n 2<\/jats:sup>\n , and in patients who crossed over from placebo to ravulizumab at week 26, it was \u22126.3 (\u22129.7 to \u22122.9) ml\/min per 1.73 m\n 2<\/jats:sup>\n . Ravulizumab was well tolerated, with an adverse event profile similar to that for placebo.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n An early, sustained, and clinically meaningful reduction in proteinuria and trend toward stabilization of eGFR were observed with ravulizumab versus placebo. A phase 3 trial (NCT06291376) is enrolling.<\/jats:p>\n <\/jats:sec>\n \n Clinical Trial registry name and registration number:<\/jats:title>\n Study of Ravulizumab in Proliferative Lupus Nephritis or IgA Nephropathy, NCT04564339.<\/jats:p>\n <\/jats:sec>\n \n Podcast<\/jats:title>\n This article contains a podcast at https:\/\/dts.podtrac.com\/redirect.mp3\/www.asn-online.org\/media\/podcast\/JASN\/2024_10_26_KTS_October2024.mp3<\/jats:p>\n <\/jats:sec>","DOI":"10.1681\/asn.0000000534","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T21:00:12Z","timestamp":1729890012000},"page":"645-656","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":72,"title":["Efficacy and Safety of Ravulizumab in IgA Nephropathy"],"prefix":"10.1681","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3906-7934","authenticated-orcid":false,"given":"Richard","family":"Lafayette","sequence":"first","affiliation":[{"name":"Stanford Glomerular Disease Center, Stanford University Medical Center, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Tumlin","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Fenoglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7718-3464","authenticated-orcid":false,"given":"Jessica","family":"Kaufeld","sequence":"additional","affiliation":[{"name":"Hannover Medical School, Department of Nephrology and Hypertension, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8148-3731","authenticated-orcid":false,"given":"Miguel \u00c1ngel","family":"P\u00e9rez Valdivia","sequence":"additional","affiliation":[{"name":"Servicio de Nefrolog\u00eda, UGC Urolog\u00eda-Nefrolog\u00eda, Hospital Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai-Szu","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Shuang-Ho Hospital, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0848-130X","authenticated-orcid":false,"given":"Shih-Han","family":"Susan Huang","sequence":"additional","affiliation":[{"name":"Kidney Clinical Research Unit, London Health Sciences Center, East London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7720-8297","authenticated-orcid":false,"given":"Eric","family":"Alamartine","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie, H\u00f4pital Nord CHU Saint-\u00c9tienne, Saint-\u00c9tienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5034-0527","authenticated-orcid":false,"given":"Sung Gyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yee","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kateifides","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3289-3476","authenticated-orcid":false,"given":"Kara","family":"Rice","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3853-0114","authenticated-orcid":false,"given":"Katherine","family":"Garlo","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9063-7229","authenticated-orcid":false,"given":"Jonathan","family":"Barratt","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the SANCTUARY Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"issue":"4S","key":"B1-20250930","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int."},{"issue":"10433","key":"B2-20250930","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(23)02843-X","article-title":"Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort","volume":"403","author":"Wong","year":"2024","journal-title":"Lancet."},{"issue":"3","key":"B3-20250930","doi-asserted-by":"crossref","first-page":"e91756","DOI":"10.1371\/journal.pone.0091756","article-title":"Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan","volume":"9","author":"Moriyama","year":"2014","journal-title":"PLoS One."},{"issue":"5","key":"B4-20250930","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1681\/ASN.2018101017","article-title":"Mortality in IgA nephropathy: a nationwide population-based cohort study","volume":"30","author":"Jarrick","year":"2019","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B5-20250930","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ekir.2017.08.008","article-title":"Life expectancy for patients from the Southeastern United States with IgA nephropathy","volume":"3","author":"Hastings","year":"2018","journal-title":"Kidney Int Rep."},{"issue":"9","key":"B6-20250930","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.ekir.2023.06.016","article-title":"Clinicopathological characteristics of adult IgA nephropathy in the United States","volume":"8","author":"Caster","year":"2023","journal-title":"Kidney Int Rep."},{"issue":"10433","key":"B7-20250930","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(24)00198-3","article-title":"The impact of rare kidney diseases on kidney failure","volume":"403","author":"Aiyegbusi","year":"2024","journal-title":"Lancet."},{"issue":"6","key":"B8-20250930","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol."},{"issue":"2","key":"B9-20250930","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1053\/j.ajkd.2023.12.016","article-title":"Time-varying proteinuria and progression of IgA nephropathy: a cohort study","volume":"84","author":"Tang","year":"2024","journal-title":"Am J Kidney Dis."},{"issue":"12","key":"B10-20250930","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"J Am Soc Nephrol."},{"issue":"3","key":"B11-20250930","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol."},{"issue":"10405","key":"B13-20250930","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet."},{"issue":"12","key":"B16-20250930","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1016\/j.ekir.2023.09.034","article-title":"Clinical practice patterns in IgA nephropathy: a global questionnaire-based survey","volume":"8","author":"Bansal","year":"2023","journal-title":"Kidney Int Rep."},{"issue":"1","key":"B17-20250930","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int."},{"issue":"1","key":"B18-20250930","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","article-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial","volume":"12","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"12","key":"B19-20250930","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1093\/ndt\/gfad140","article-title":"The complement system in IgAN: mechanistic context for therapeutic opportunities","volume":"38","author":"Duval","year":"2023","journal-title":"Nephrol Dial Transplant."},{"issue":"10","key":"B20-20250930","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol."},{"key":"B21-20250930","doi-asserted-by":"crossref","first-page":"16001","DOI":"10.1038\/nrdp.2016.1","article-title":"IgA nephropathy","volume":"2","author":"Lai","year":"2016","journal-title":"Nat Rev Dis Primers."},{"key":"B22-20250930","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3389\/fimmu.2019.00504","article-title":"The emerging role of complement proteins as a target for therapy of IgA nephropathy","volume":"10","author":"Rizk","year":"2019","journal-title":"Front Immunol."},{"key":"B23-20250930","doi-asserted-by":"crossref","first-page":"599974","DOI":"10.3389\/fimmu.2020.599974","article-title":"Deposition of the membrane attack complex in healthy and diseased human kidneys","volume":"11","author":"Koopman","year":"2020","journal-title":"Front Immunol."},{"key":"B24-20250930","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molimm.2021.09.010","article-title":"Is complement the main accomplice in IgA nephropathy? From initial observations to potential complement-targeted therapies","volume":"140","author":"Le Stang","year":"2021","journal-title":"Mol Immunol."},{"issue":"20","key":"B25-20250930","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.3390\/jcm10204715","article-title":"The contribution of complement to the pathogenesis of IgA nephropathy: are complement-targeted therapies moving from rare disorders to more common diseases?","volume":"10","author":"Poppelaars","year":"2021","journal-title":"J Clin Med."},{"issue":"4","key":"B26-20250930","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/00365590801943241","article-title":"C5b-9 glomerular deposition and tubular \u03b13\u03b21-integrin expression are implicated in the development of chronic lesions and predict renal function outcome in immunoglobulin A nephropathy","volume":"42","author":"Stangou","year":"2008","journal-title":"Scand J Urol Nephrol."},{"issue":"7","key":"B27-20250930","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/ndt\/10.7.1166","article-title":"The pathogenetic significance of C5b-9 in IgA nephropathy","volume":"10","author":"Alexopoulos","year":"1995","journal-title":"Nephrol Dial Transplant."},{"key":"B28-20250930","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12014-017-9165-x","article-title":"Glomerular abundance of complement proteins characterized by proteomic analysis of laser-captured microdissected glomeruli associates with progressive disease in IgA nephropathy","volume":"14","author":"Paunas","year":"2017","journal-title":"Clin Proteomics."},{"key":"B29-20250930","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1471-2369-12-64","article-title":"Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function","volume":"12","author":"Onda","year":"2011","journal-title":"BMC Nephrol."},{"issue":"1","key":"B31-20250930","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis."},{"issue":"10084","key":"B32-20250930","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstrom","year":"2017","journal-title":"Lancet."},{"issue":"9","key":"B33-20250930","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2019010007","article-title":"GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials","volume":"30","author":"Inker","year":"2019","journal-title":"J Am Soc Nephrol."},{"issue":"4","key":"B34-20250930","doi-asserted-by":"crossref","first-page":"S506","DOI":"10.1016\/j.ekir.2024.02.1414","article-title":"WCN24-1506 efficacy and safety of iptacopan in patients with IgA nephropathy: interim results from the phase 3 APPLAUSE-IgAN study","volume":"9","author":"Perkovic","year":"2024","journal-title":"Kidney Int Rep."},{"issue":"suppl 1","key":"B35-20250930","article-title":"#388 IONIS-FB-LRx, an antisense oligonucleotide to complement factor B for treatment of IgA nephropathy","volume":"39","author":"Hladunewich","year":"2024","journal-title":"Nephrol Dial Transplant."},{"issue":"3","key":"B36-20250930","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.ekir.2023.02.124","article-title":"WCN23-0141 A phase 2 study evaluating the efficacy and safety of Alxn2050, a complement factor D inhibitor, in immunoglobulin A nephropathy or proliferative lupus nephritis (Ln)","volume":"8","author":"Bapat","year":"2023","journal-title":"Kidney Int Rep."},{"issue":"1","key":"B37-20250930","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N Engl J Med."},{"issue":"6","key":"B38-20250930","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int."},{"issue":"3","key":"B39-20250930","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep."},{"issue":"suppl 1","key":"B40-20250930","article-title":"#4337 Updated interim results of a phase 1\/2 study of BION-1301 in patients with IGA nephropathy","volume":"38","author":"Barratt","year":"2023","journal-title":"Nephrol Dial Transplant."},{"issue":"suppl 1","key":"B41-20250930","first-page":"i252","article-title":"#425 Felzartamab (anti-CD38) in patients with IgA nephropathy\u2014interim results from the IGNAZ study","volume":"39","author":"Floege","year":"2024","journal-title":"Nephrol Dial Transplant."},{"issue":"suppl 1","key":"B42-20250930","article-title":"#1342 Updated results from the RUBY-3 study of povetacicept, an enhanced dual BAFF\/APRIL antagonist, in autoantibody-associated glomerulonephritis","volume":"39","author":"Madan","year":"2024","journal-title":"Nephrol Dial Transplant."}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000000534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:35:37Z","timestamp":1786131337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000000534"}},"subtitle":["A Phase 2 Randomized Double-Blind Placebo-Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.0000000534","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]},"assertion":[{"value":"2024-08-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}